

**CHRD Antibody (C-term) Blocking Peptide**  
**Synthetic peptide**  
**Catalog # BP1416b****Specification**

---

**CHRD Antibody (C-term) Blocking Peptide - Product Information**Primary Accession [Q9H2X0](#)**CHRD Antibody (C-term) Blocking Peptide - Additional Information****Gene ID** 8646**Other Names**  
Chordin, CHRD**Target/Specificity**

The synthetic peptide sequence used to generate the antibody [AP1416b](/product/products/AP1416b) was selected from the C-term region of human CHRD. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**CHRD Antibody (C-term) Blocking Peptide - Protein Information****Name** CHRD**Function**

Dorsalizing factor. Key developmental protein that dorsalizes early vertebrate embryonic tissues by binding to ventralizing TGF-beta family bone morphogenetic proteins (BMPs) and sequestering them in latent complexes (By similarity).

**Cellular Location**

Secreted.

**Tissue Location**

Expressed at the highest level in liver.

**CHRD Antibody (C-term) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

**CHRD Antibody (C-term) Blocking Peptide - Images****CHRD Antibody (C-term) Blocking Peptide - Background**

CHRD is a secreted protein that dorsalizes early vertebrate embryonic tissues by binding to ventralizing TGF-beta-like bone morphogenetic proteins and sequestering them in latent complexes. This protein may also have roles in organogenesis and during adulthood.

**CHRD Antibody (C-term) Blocking Peptide - References**

Lim,J., Cell 125 (4), 801-814 (2006)Moll,F., FASEB J. 20 (2), 240-250 (2006)